ストックスクリーナーアプリを入手
10.66
18.84%
1.69
プレマーケット:
10.66
前日終値:
$8.97
開ける：
$9.4
24時間の取引高:
45,112
Relative Volume:
1.78
時価総額：
$22.95M
収益：
-
当期純損益:
$-563.30K
株価収益率:
-53.41
EPS:
-0.1996
ネットキャッシュフロー:
$-22.23M
1週間 パフォーマンス:
+30.57%
1か月 パフォーマンス:
+39.16%
6か月 パフォーマンス:
-56.78%
1年 パフォーマンス:
-51.76%
1日の値動き範囲:
$9.40
$11.47
1週間の範囲:
$8.0977
$11.47
52週間の値動き範囲:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
PMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.66 | 19.31M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Promis Neurosciences Inc (PMN) 最新ニュース
Aug Breakouts: Whats next for ProMIS Neurosciences Inc stockEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
How cyclical is ProMIS Neurosciences Inc.’s revenue streamMarket Activity Recap & Daily Profit Maximizing Trade Tips - bollywoodhelpline.com
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Quarterly Earnings: Is ProMIS Neurosciences Inc benefiting from innovation trends2025 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Aug Breakouts: Can ProMIS Neurosciences Inc continue delivering strong returnsBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
Bull Run: What are analysts price targets for DMAAMarket Growth Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
Gap Down: Can ProMIS Neurosciences Inc continue delivering strong returnsPortfolio Profit Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Bull Bear: Whats ProMIS Neurosciences Incs historical returnTreasury Yields & Short-Term Trading Alerts - baoquankhu1.vn
ProMIS Neurosciences regains Nasdaq compliance - MSN
US Market Wrap: Is FTAIN exposed to political riskJuly 2025 Gainers & Target Return Focused Stock Picks - baoquankhu1.vn
Gains Report: Does ProMIS Neurosciences Inc outperform in volatile marketsQuarterly Trade Review & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
What is the cash position of ProMIS Neurosciences Inc2025 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Market Moves: Can ProMIS Neurosciences Inc continue delivering strong returnsMarket Growth Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Institution Moves: What is ProMIS Neurosciences Incs P E ratio telling usEarnings Overview Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
US Market Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Volume & High Win Rate Trade Tips - baoquankhu1.vn
Why ProMIS Neurosciences Inc. stock appeals to analystsJuly 2025 Action & Weekly Market Pulse Alerts - Улправда
Is ProMIS Neurosciences Inc. (23J0) stock considered safe havenBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Can ProMIS Neurosciences Inc. stock beat analyst upgradesWeekly Trend Report & Community Consensus Trade Signals - Улправда
How dovish Fed policy supports ProMIS Neurosciences Inc. (23J0) stockPortfolio Return Report & Reliable Intraday Trade Plans - Улправда
Setup Watch: How dovish Fed policy supports ProMIS Neurosciences Inc 23J0 stockJuly 2025 Market Mood & Smart Swing Trading Alerts - moha.gov.vn
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Guidance Update: Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansionWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansion2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. (23J0) stock could outperform next yearQuarterly Trade Summary & Consistent Profit Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. stock appeals to dividend seekers2025 Volume Leaders & Fast Momentum Stock Entry Tips - DonanımHaber
Why ProMIS Neurosciences Inc. stock remains on watchlistsGold Moves & Safe Capital Growth Plans - DonanımHaber
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial By Investing.com - Investing.com South Africa
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzh - GuruFocus
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial - Investing.com
ProMIS Neurosciences exceeds target enrollment in Precise-AD phase 1b clinical trial - marketscreener.com
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease - The Manila Times
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ... - Caledonian Record
PRN_FinancialWrapper - FinancialContent
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule - Investing.com Australia
ProMIS Neurosciences Regains Nasdaq Compliance - TipRanks
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
ProMIS Neurosciences Announces Third Quarter 2019 Results - PR Newswire
ProMIS Neurosciences announces publication highlighting PMN310 - MSN
Cash per share of ProMIS Neurosciences Inc. – DUS:23J - TradingView — Track All Markets
ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com - Investing.com Nigeria
ProMIS Neurosciences shareholders approve share consolidation proposal - Investing.com
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - The Manila Times
Fortrea (NASDAQ:FTRE) & Promis Neurosciences (NASDAQ:PMN) Head-To-Head Review - Defense World
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):